202 related articles for article (PubMed ID: 22653658)
1. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Sellebjerg F; Hesse D; Limborg S; Lund H; Søndergaard HB; Krakauer M; Sørensen PS
Mult Scler; 2013 Feb; 19(2):179-87. PubMed ID: 22653658
[TBL] [Abstract][Full Text] [Related]
2. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients.
Ruggieri M; Pica C; Lia A; Zimatore GB; Modesto M; Di Liddo E; Specchio LM; Livrea P; Trojano M; Avolio C
J Neuroimmunol; 2008 Jul; 197(2):140-6. PubMed ID: 18555539
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T; Schrempf W
Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
[TBL] [Abstract][Full Text] [Related]
6. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J
J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090
[TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.
Sanna A; Fois ML; Arru G; Huang YM; Link H; Pugliatti M; Rosati G; Sotgiu S
Clin Exp Immunol; 2006 Feb; 143(2):357-62. PubMed ID: 16412061
[TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.
Sellebjerg F; Hedegaard CJ; Krakauer M; Hesse D; Lund H; Nielsen CH; Søndergaard HB; Sørensen PS
Mult Scler; 2012 Mar; 18(3):305-13. PubMed ID: 22020419
[TBL] [Abstract][Full Text] [Related]
9. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J
J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Karandikar NJ; Crawford MP; Yan X; Ratts RB; Brenchley JM; Ambrozak DR; Lovett-Racke AE; Frohman EM; Stastny P; Douek DC; Koup RA; Racke MK
J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
[TBL] [Abstract][Full Text] [Related]
11. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
12. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.
Putheti P; Soderstrom M; Link H; Huang YM
J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106
[TBL] [Abstract][Full Text] [Related]
13. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
Blanco Y; Moral EA; Costa M; Gómez-Choco M; Torres-Peraza JF; Alonso-Magdalena L; Alberch J; Jaraquemada D; Arbizu T; Graus F; Saiz A
Neurosci Lett; 2006 Oct; 406(3):270-5. PubMed ID: 16934924
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Carrieri PB; Carbone F; Perna F; Bruzzese D; La Rocca C; Galgani M; Montella S; Petracca M; Florio C; Maniscalco GT; Spitaleri DL; Iuliano G; Tedeschi G; Della Corte M; Bonavita S; Matarese G
Metabolism; 2015 Sep; 64(9):1112-21. PubMed ID: 25986733
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
[TBL] [Abstract][Full Text] [Related]
17. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
Bar-Or A; Fawaz L; Fan B; Darlington PJ; Rieger A; Ghorayeb C; Calabresi PA; Waubant E; Hauser SL; Zhang J; Smith CH
Ann Neurol; 2010 Apr; 67(4):452-61. PubMed ID: 20437580
[TBL] [Abstract][Full Text] [Related]
18. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate.
Chiarini M; Sottini A; Ghidini C; Zanotti C; Serana F; Rottoli M; Zaffaroni M; Bergamaschi R; Cordioli C; Capra R; Imberti L
Mult Scler; 2010 Feb; 16(2):218-27. PubMed ID: 20007428
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.
Weber MS; Starck M; Wagenpfeil S; Meinl E; Hohlfeld R; Farina C
Brain; 2004 Jun; 127(Pt 6):1370-8. PubMed ID: 15090474
[TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]